A	B	C	D	E	F	G	H	I	J	K
1
2		Brand	Generic	Indication	Economics	Admin	IP		Price	4.86
3		Yutrepia	treprostinil	PAH	1	DPI			Shares	64.344476	Q122
4		None	treprostinil	PAH	50% Sandoz, Chengdu	IV			MC	312.71415336
5									Cash	111.794	Q122
6									Debt	19.476	Q122
7									EV	220.39615336000003
8		Morrisville, NC
9									PPE	5	Q122
10		6/27/22: Russell index addition							AD	326	Q122
11		6/24/22: inducements
12		6/20/22: CMO appointed							RareGen, LLC, renamed Liquidia PAH, LLC
13		6/9/22: PHA presentation							Acquired 11/18/2020 pursuant to 8/3/20 agreement
14		6/7/22: investor conference							Issued 5.55m shares to RareGen holders, followed by 617k.
15		6/2/22: investor conference							Liquidia Technologies, Inc.
16		5/16/22: ATS presentation							Caligan Partners LP PIPE
17		5/12/22: Q122 results							8.6m shares at 2.52 for $22m
18		5/5/22: Q122 date
19		4/25/22: inducements
20		4/18/22: Closed financing for $54m net.							CEO: Roger Jeffs replaced Damian deGoa. Neal Fowler early CEO.
21		4/12/22: Sold 11.3m shares at 5.10.							CFO: Michael Kaseta
22		1/3/22: Jeffs hired							CMO: Rajeev Saggar
23		11/2021: Yutrepia tentatively approved
24		4/2021: 8.6m shares sold at 2.52 for 21.7m.							PRINT: Particle Replication In Non-Wetting Templates
25		11/18/20: completed RareGen acquisition for 5.55m shares.							Discontinued: LIQ865 for pain
26		2/2/2018: files S-1. LIQ861 is in Phase 3.							PBM owns 9.3% of company
27		7/2012: $14m raise (amended 3/2011 filing).							Chasm Technologies, Inc.
28		3/2011: $10m raise.							Manufacturing consulting, including royalties.
29		5/2010: $25m raise (amended 1/2010 filing).							LGM Pharma LLC
30		1/2010: $20m raise (amended 2009 filing).							Yutrepia API
31		7/2009: $7m raise.
32		3/2007: $16m Series B round with NEA
33		5/2006: $6m Series A round
34		2/2005: $2m round
35		6/2004: formation in NC by Joseph DeSimone